Granado-Casas Minerva, Martínez-Alonso Montserrat, Alcubierre Nuria, Ramírez-Morros Anna, Hernández Marta, Castelblanco Esmeralda, Torres-Puiggros Joan, Mauricio Didac
Department of Endocrinology and Nutrition, Centre for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain.
Biomedical Research Institute of Lleida, University of Lleida, Lleida, Spain.
PeerJ. 2017 Oct 18;5:e3928. doi: 10.7717/peerj.3928. eCollection 2017.
Our main aim was to assess the quality of life (QoL) and treatment satisfaction (TS) of subjects with LADA (latent autoimmune diabetes of the adult) and compare these measures with those of patients with other diabetes types, i.e., type 1 (T1DM) and type 2 diabetes mellitus (T2DM).
This was a cross-sectional study with a total of 48 patients with LADA, 297 patients with T2DM and 124 with T1DM. The Audit of Diabetes-Dependent Quality of Life (ADDQoL-19) questionnaire and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) were administered. Relevant clinical variables were also assessed. The data analysis included comparisons between groups and multivariate linear models.
The LADA patients presented lower diabetes-specific QoL ( = 0.045) and average weighted impact scores ( = 0.007) than the T2DM patients. The subgroup of LADA patients with diabetic retinopathy (DR) who were treated with insulin had a lower ADDQoL average weighted impact score than the other diabetic groups. Although the overall measure of TS was not different between the LADA and T2DM ( = 0.389) and T1DM ( = 0.091) groups, the patients with LADA showed a poorer hyperglycemic frequency perception than the T2DM patients ( < 0.001) and an improved frequency of hypoglycemic perception compared with the T1DM patients ( = 0.021).
The current findings suggest a poorer quality of life, especially in terms of DR and insulin treatment, among patients with LADA compared with those with T1DM and T2DM. Hyperglycemia frequency perception was also poorer in the LADA patients than in the T1DM and T2DM patients. Further research with prospective studies and a large number of patients is necessary.
我们的主要目的是评估成人隐匿性自身免疫性糖尿病(LADA)患者的生活质量(QoL)和治疗满意度(TS),并将这些指标与其他糖尿病类型患者,即1型糖尿病(T1DM)和2型糖尿病(T2DM)患者的相应指标进行比较。
这是一项横断面研究,共有48例LADA患者、297例T2DM患者和124例T1DM患者。采用糖尿病相关生活质量评估量表(ADDQoL-19)问卷和糖尿病治疗满意度问卷(DTSQ)进行调查。同时评估相关临床变量。数据分析包括组间比较和多元线性模型。
与T2DM患者相比,LADA患者的糖尿病特异性生活质量(P = 0.045)和平均加权影响得分(P = 0.007)较低。接受胰岛素治疗的患有糖尿病视网膜病变(DR)的LADA患者亚组的ADDQoL平均加权影响得分低于其他糖尿病组。尽管LADA组与T2DM组(P = 0.389)和T1DM组(P = 0.091)的总体治疗满意度无差异,但LADA患者对高血糖发生频率的感知比T2DM患者差(P < 0.001),而与T1DM患者相比,对低血糖发生频率的感知有所改善(P = 0.021)。
目前的研究结果表明,与T1DM和T2DM患者相比,LADA患者的生活质量较差,尤其是在糖尿病视网膜病变和胰岛素治疗方面。LADA患者对高血糖发生频率的感知也比T1DM和T2DM患者差。有必要进行更多前瞻性研究和纳入大量患者的进一步研究。